Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph L Kim

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Cureus|November 19, 2025
Therapy Dogs at the Bedside: A Scoping Review of Pet Therapy in Adult Intensive Care UnitsJoseph L Kim
Cureus|July 24, 2025
Intensive Care Unit-Based Medical Education for Medical Students: A Scoping ReviewJoseph L Kim, Yohan Kim
Cureus|December 12, 2024
Acute Bilateral Vocal Cord Paralysis in a Patient With Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Limbic EncephalitisJoseph L Kim, Yohan Kim, Andres Saenz
Nature Communications|September 11, 2014
The landscape of kinase fusions in cancerNicolas Stransky, Ethan Cerami, Stefanie Schalm, et al.
Molecular & Cellular Oncology|September 26, 2018
Targeting kinases with precisionAlexandra K Gardino, Erica K Evans, Joseph L Kim, et al.
Journal of Medicinal Chemistry|March 10, 2026
Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GISTLudivine Moine, Wei Hu, Alison Davis, et al.
Cancer Discovery|March 18, 2015
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling PathwayMargit Hagel, Chandra Miduturu, Michael Sheets, et al.
Molecular Cancer Therapeutics|July 29, 2010
Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growthJosette Carnahan, Pedro J Beltran, Carol Babij, et al.
Bioorganic & Medicinal Chemistry|April 18, 2016
Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profilingLongbin Liu, Matthew R Lee, Joseph L Kim, et al.
Bioorganic & Medicinal Chemistry|May 29, 2016
Corrigendum to "Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling" [Bioorg. Med. Chem. 24 (2016) 2215-2234]Longbin Liu, Matthew R Lee, Joseph L Kim, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Cureus|November 19, 2025
Therapy Dogs at the Bedside: A Scoping Review of Pet Therapy in Adult Intensive Care UnitsJoseph L Kim
Cureus|July 24, 2025
Intensive Care Unit-Based Medical Education for Medical Students: A Scoping ReviewJoseph L Kim, Yohan Kim
Cureus|December 12, 2024
Acute Bilateral Vocal Cord Paralysis in a Patient With Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Limbic EncephalitisJoseph L Kim, Yohan Kim, Andres Saenz
Nature Communications|September 11, 2014
The landscape of kinase fusions in cancerNicolas Stransky, Ethan Cerami, Stefanie Schalm, et al.
Molecular & Cellular Oncology|September 26, 2018
Targeting kinases with precisionAlexandra K Gardino, Erica K Evans, Joseph L Kim, et al.
Journal of Medicinal Chemistry|March 10, 2026
Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GISTLudivine Moine, Wei Hu, Alison Davis, et al.
Cancer Discovery|March 18, 2015
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling PathwayMargit Hagel, Chandra Miduturu, Michael Sheets, et al.
Molecular Cancer Therapeutics|July 29, 2010
Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growthJosette Carnahan, Pedro J Beltran, Carol Babij, et al.
Bioorganic & Medicinal Chemistry|April 18, 2016
Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profilingLongbin Liu, Matthew R Lee, Joseph L Kim, et al.
Bioorganic & Medicinal Chemistry|May 29, 2016
Corrigendum to "Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling" [Bioorg. Med. Chem. 24 (2016) 2215-2234]Longbin Liu, Matthew R Lee, Joseph L Kim, et al.
Pageof 3